Evaluating the effect of vitex agnus castus on treatment of premenstrual syndrome

Evaluating the effect of vitex agnus castus on treatment of premenstrual syndrome among students of Tehran University of Medical Sciences and Tehran University

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201101035541N1

Enrollment

116

Registered

2011-03-31

Start date

2006-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual syndrome. Premenstrual tension syndrome

Interventions

Intervention 1: Participants in drug group took tablet of vitex agnus castus made by Goldaru pharmaceutical Company in Esfahan (contain 3.2- 4.8 mg dry extract of vitex fruit, equal 0.42-0.58 mg Auc

Treatment - Drugs

Placebo

Participants in drug group took tablet of vitex agnus castus made by Goldaru pharmaceutical Company in Esfahan (contain 3.2- 4.8 mg dry extract of vitex fruit, equal 0.42-0.58 mg Aucubin), one table

Participants in placebo group took tablet of placebo made by Goldaru Pharmaceutical Company in Esfahan (contain Magnesium Astyaarat 1 % and Starch), one tablet daily for two cycles.

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Age 18 and above 2- Single 3- Regular menstruation (interval: 24-35 days, duration: 2-8 days) in last year 4- Contemporary diagnosis of pms based on DSM-IV 5- Confirmed diagnosis of pms based on two screening cycles Exclusion criteria: 1- Diagnosed physical or mental diseases 2- Using hormonal drugs, agonist or antagonist of dopamine ,or vitamins 3- Using antidepressant or herbal drugs 4- Participation in other same trials

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Total symptoms of premenstrual syndrome. Timepoint: before treatment (two screening cycles)and after treatment (two treatment cycles). Method of measurement: Daily Symptoms Rating(DSR)contain 18 symptoms of premenstrual syndrome (10 psychological and 8 physical symptoms).;Psychological symptoms of premenstrual syndrome. Timepoint: before treatment (two screening cycles)and after treatment (two treatment cycles). Method of measurement: Daily Symptom Rating (DSR) (contain 10 psychological symptoms).;Physical symptoms of premenstrual syndrome. Timepoint: before treatment (two screening cycles)and after treatment (two treatment cycles). Method of measurement: Daily Symptom Rating (DSR) (contain 8 physical symptoms).	—

Measure

Time frame

Total symptoms of premenstrual syndrome. Timepoint: before treatment (two screening cycles)and after treatment (two treatment cycles). Method of measurement: Daily Symptoms Rating(DSR)contain 18 symptoms of premenstrual syndrome (10 psychological and 8 physical symptoms).;Psychological symptoms of premenstrual syndrome. Timepoint: before treatment (two screening cycles)and after treatment (two treatment cycles). Method of measurement: Daily Symptom Rating (DSR) (contain 10 psychological symptoms).;Physical symptoms of premenstrual syndrome. Timepoint: before treatment (two screening cycles)and after treatment (two treatment cycles). Method of measurement: Daily Symptom Rating (DSR) (contain 8 physical symptoms).

—

Secondary

Measure	Time frame
Side effects. Timepoint: in two treatment cycles. Method of measurement: through check list of side effects.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Moradi

Australian National University

maryam.moradi@anu.edu.au061262443655

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026